Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Women with premature ovarian insufficiency on HT likely to have poor sleep quality

10 Aug 2019

Women who have premature ovarian insufficiency (POI) and are receiving hormone therapy (HT) appear to have poor sleep quality, taking longer to fall asleep and experiencing greater fatigue, according to a recent study.

The cross-sectional study involved 61 women with POI receiving HT (POI group; mean age, 35.03 years) and an identical number of age-matched women with preserved ovarian function (control group; mean age, 34.49 years).

Researchers evaluated sleep quality and fatigue using the Pittsburgh Sleep Quality Index (PSQI) and Chalder Fatigue Scale, respectively. They performed correlation analysis, the Mann-Whitney, chi-square, or Fisher test to compare the said outcomes between the POI and control groups.

Results for the PSQI evaluation showed no significant between-group difference, with mean scores of 7.69 in the POI group and 8.03 in the control group (p=0.79).

However, women in the POI group had higher and therefore worse scores for the sleep latency component (mean, 1.74 and 1.18, respectively; p<0.001) and were more likely to use sleep medications (mean, 1.28 and 0.85; p=0.008). Furthermore, fatigue index was markedly higher than in the control group (mean, 5.25 and 3.49, respectively; p<0.001).

In the POI group, sleep quality was graded as poor in 69 percent of women, while fatigue was present in 59 percent.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.